Welgene Biotech Co.,Ltd. (6661.TWO)

TWD 20.45

(-0.49%)

Market Cap (In TWD)

476.57 Million

Revenue (In TWD)

280.54 Million

Net Income (In TWD)

-2.64 Million

Avg. Volume

13.4 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
22.0-39.4
PE
409.0
EPS
0.05
Beta Value
0.343
ISIN
TW0006661002
CUSIP
-
CIK
-
Shares
23304200.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Dr. Yi Xing Lin
Employee Count
-
Website
https://www.welgene.com.tw
Ipo Date
2017-10-23
Details
Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.